Jim Cramer's Mad Dash: Starbucks and Celgene Have Upside

NEW YORK (TheStreet) -- Shares of Starbucks (SBUX) caught an upgrade from UBS to buy from hold, while the analyst also bumped the price target to $87 from $80. 

On CNBC's "Cramer's Mad Dash" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, took at look at this "classic growth stock."

The stock has had trouble gaining upside momentum due to rising coffee costs, he reasoned.

However, CEO Howard Schultz has had to deal with rising input costs before, and has well positioned his company to deflect this rapid rise. 

Cramer added that investors are not paying too much for shares of Starbucks at current levels and he likes this analyst's call "very much." 

Turning to Celgene (CELG), Credit Suisse boosted its price target on the stock to $225 from $210. 

The analyst reasoned that Celgene's pipeline is not being fully recognized, and Cramer seemed to agree. The advancements in creating possible cures for Crohn's disease and psoriatic arthritis are incredible and could be huge for Celgene, he concluded.

-- Written by Bret Kenwell in Petoskey, Mich.

IBM Fights for Respect and Relevance on Rough Seas of Investor Confidence

Why Big Car Companies Don't Give A Rat's Ass About Tesla

5 Reasons to Change Your Outlook on Emerging Markets

Why SolarCity Is Shining Once Again for Investors

At the time of publication, Cramer's Action Alerts PLUS holds CELG.

More from Opinion

Why a Global Stock Market Crash Is Coming

Why a Global Stock Market Crash Is Coming

3 New Investing Myths That Must Be Busted

3 New Investing Myths That Must Be Busted

Sears CEO Eddie Lampert Looks Like He Is Sucking Company Dry

Sears CEO Eddie Lampert Looks Like He Is Sucking Company Dry

Nasdaq Exec: Exchange Is 'All-In' on Using Blockchain Technology

Nasdaq Exec: Exchange Is 'All-In' on Using Blockchain Technology

It's Dumb to Think Legalizing Weed Is Still a Political Issue

It's Dumb to Think Legalizing Weed Is Still a Political Issue